Tiantan Biological board approves disposal of Shanghai Shengong project

Beijing Tiantan Biological Products Co. (the "Company") announced that its board of directors, at a meeting held on September 26, 2025, approved the resolution to initiate the disposal of the Shanghai Shengong Biological Products Operating Co., Ltd. project. The meeting was convened via electronic means on September 19, 2025, with all nine eligible directors participating and voting unanimously. This resolution had received prior approval from the board’s Strategy and Investment Committee.

Shanghai Shengong Biological Products Operating Co., Ltd. ("Shengong Company") reported operating revenues of 1,197 yuan and 808 yuan for 2024 and January-June 2025, respectively, representing 0.2% and 0.26% of the Company's total operating revenue. Its net profits for the same periods were 23 yuan and -72 yuan, accounting for 0.01% and -0.08% of the Company's net profit. The January-June 2025 financial data for Shengong Company are unaudited.

The board's approval is solely for the project's disposal initiation. The specific disposal plan remains undetermined, requiring further audit, evaluation, and board approval in accordance with relevant regulations. Investors are advised to note the inherent uncertainties in the finalization and implementation of the disposal plan.